{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:18:58Z","timestamp":1761898738151,"version":"build-2065373602"},"reference-count":6,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.clinre.2021.101826","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T03:00:31Z","timestamp":1635476431000},"page":"101826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Can statins finally provide the breakthrough in the treatment of non-alcoholic fatty liver disease?"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7627-1016","authenticated-orcid":false,"given":"Abia","family":"Shahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-7137","authenticated-orcid":false,"given":"Huzaifa Ahmad","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2021.101826_bib0001","article-title":"Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis","author":"Fatima","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.clinre.2021.101826_bib0002","first-page":"1","article-title":"What study designs can be considered for inclusion in an EPOC review and what should they be called?","year":"2015","journal-title":"Cochrane Libr"},{"key":"10.1016\/j.clinre.2021.101826_bib0003","series-title":"Cochrane handb. syst. rev. interv.","article-title":"Chapter 25: assessing risk of bias in a non-randomized study","author":"Sterne","year":"2019"},{"key":"10.1016\/j.clinre.2021.101826_bib0004","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1017\/S2045796016000809","article-title":"Pre-post effect sizes should be avoided in meta-analyses","volume":"26","author":"Cuijpers","year":"2017","journal-title":"Epidemiol Psychiatr Sci"},{"key":"10.1016\/j.clinre.2021.101826_bib0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.arcmed.2013.12.003","article-title":"Statin use is not associated with presence of and severity of nonalcoholic fatty liver disease","volume":"45","author":"Oni","year":"2014","journal-title":"Arch Med Res"},{"key":"10.1016\/j.clinre.2021.101826_bib0006","series-title":"Cochrane handb. syst. rev. interv.","article-title":"Chapter 24: including non-randomized studies on intervention effects","author":"Reeves","year":"2019"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740121002047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740121002047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:32:00Z","timestamp":1761895920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740121002047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2210740121002047"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2021.101826","relation":{},"ISSN":["2210-7401"],"issn-type":[{"type":"print","value":"2210-7401"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can statins finally provide the breakthrough in the treatment of non-alcoholic fatty liver disease?","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2021.101826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101826"}}